Understanding the biology of MPN to improve patient care

Updated 23 Nov 2018
Lead researcher - Professor Anthony Green, University of Cambridge
The myeloproliferative neoplasms - from molecular mechanisms to improved patient management
Amount awarded: £1,798,136
Award start date: 01 Jul 2016
Recruitment start date: 13 Jul 2017
Award duration: 6 years

The myeloproliferative neoplasms (MPNs) represent an unmet clinical need for several reasons: there are large number of patients (~ 40,000 in UK); diagnosis can be difficult; we lack any effective treatments for advanced phase disease; leukemic transformation is invariably fatal; novel agents including JAK2 inhibitors are in clinical trials but do not appear to affect the natural history of the mutant clone.
Our strategy continues to focus on understanding the surprisingly complex biology of human myeloproliferative neoplasms (MPNs) and translating the insights thus gained into improved diagnostic tools, prognostic predictions and new therapies. Our program continues to leverage enormous benefits in terms of scientific expertise, Europe’s largest genome institute, and the UK’s national MPN trial and sample banking structures (both based in Cambridge).